Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bionano Genomics's Enterprise Value is MXN214.9 Mil.
Bionano Genomics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was MXN-1,645.5 Mil. Therefore, Bionano Genomics's EV-to-EBIT ratio for today is -0.13.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Bionano Genomics's Enterprise Value is MXN214.9 Mil.
Bionano Genomics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was MXN-1,376.1 Mil. Therefore, Bionano Genomics's EV-to-EBITDA ratio for today is -0.16.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Bionano Genomics's Enterprise Value is MXN214.9 Mil.
Bionano Genomics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was MXN564.3 Mil. Therefore, Bionano Genomics's EV-to-Revenue ratio for today is 0.38.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Bionano Genomics's Enterprise Value is MXN214.9 Mil.
Bionano Genomics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was MXN-840.0 Mil. Therefore, Bionano Genomics's EV-to-FCF ratio for today is -0.26.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Bionano Genomics Enterprise Value Historical Data
The historical data trend for Bionano Genomics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bionano Genomics's Enterprise Value
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Bionano Genomics's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics (MEX:BNGO) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Bionano Genomics's current Enterprise Value is MXN214.9 Mil.
Bionano Genomics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,645.5 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Bionano Genomics's current Enterprise Value is MXN214.9 Mil.
Bionano Genomics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,376.1 Mil.
Bionano Genomics's current Enterprise Value is MXN214.9 Mil.
Bionano Genomics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN564.3 Mil.
Bionano Genomics's current Enterprise Value is MXN214.9 Mil.
Bionano Genomics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-840.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Bionano Genomics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEX:BNGO has been successfully added to your 